Drug intelligence / Profile preview

Zhanrong capsule

Development stage: Unknown
Lead developer: Suzhou Zanrong Pharma
Administration: Oral

Overview

Zhanrong capsule is an orally administered, non-systemic, intragastric volume-occupying agent developed for the treatment of overweight and obesity. The capsule contains a superabsorbent hydrogel that expands significantly upon contact with water in the stomach, physically occupying space to induce a sense of satiety and reduce food consumption. This mechanical mechanism of action is similar to other hydrogel-based weight loss aids like Plenity. It is currently undergoing Phase 3 clinical evaluation in China, with studies led by Peking University First Hospital to assess its efficacy and safety in weight reduction when combined with lifestyle interventions.

Brand names: Zhanrong
Other names: 展容胶囊Intragastric Zhanrong capsule

Beyond the preview

Go deeper on Zhanrong capsule.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Zhanrong capsule.

Explore the full profile